Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kelly Casteel MD

Kelly N. Casteel MD

Assistant Professor of Medicine, Section of Benign Hematology, MD Anderson Cancer Center, Houston, Texas

Dr. Kelly Casteel is faculty at the University of Texas MD Anderson Cancer Center in Houston, where her research and clinical interests include thromboembolism, platelet disorders, bleeding and thrombosis in women of childbearing age, and novel therapeutics in pediatric benign hematology.

She received her medical degree from Case Western Reserve University School of Medicine in Cleveland, Ohio, and completed combined 4-year residency training in internal medicine and pediatrics at the University of Texas McGovern Medical School, where she served as chief resident in for an additional year. She then completed an adult fellowship in hematology and medical oncology at MD Anderson Cancer Center. She is board certified in internal medicine and pediatrics and board eligible in hematology and medical oncology.

Dr. Casteel has contributed to book chapters and participated in various presentations. She is a member of the American Society of Clinical Oncology and the American Society of Hematology, among other professional organizations.

Disclosures

No reported relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Effect of P2Y12 Inhibitors on Survival Free of Organ Support in Non-Critical Hospitalized Patients With COVID-19
  2. 2021 Top Story in Benign Hematology: Antithrombotic Therapy and COVID-19
  3. Full-Dose Blood Thinners Decreased Need for Life Support and Improved Outcomes in Hospitalized COVID-19 Patients in International Trial
  4. An Overview of Immunosuppression in COVID-19 Patients
  5. Dabigatran Etexilate for the Treatment of Acute Venous Thromboembolism in Children
  6. ASH Recommendations for Managing Hematology Patients in the Context of COVID-19
  7. New Data on the Hematologic Effects of COVID-19
  8. Efficacy of Higher Doses of Anticoagulation Among Patients Hospitalized With COVID-19
  9. 2020 Top Stories in Benign Hematology: Antithrombotic Therapy and COVID-19
  10. Prevalence of VTE in Patients With Severe Novel Coronavirus Pneumonia

Recently Updated